Evidence map›Paper›PMID 37410177›Full record

ArticleMedical oncology (Northwood, London, England)2023

Proliferation inhibition and apoptosis of liver cancer cells treated by blue light irradiation.

Yun Teng, Zhige Li, Junsong Liu, Lesheng Teng, Hongdong Li

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yun TengState Key Lab of Superhard Materials, College of Physics, Jilin University, Changchun, 130012, People's Republic of China.
Zhige LiSchool of Life Sciences, Jilin University, Changchun, 130012, People's Republic of China.
Junsong LiuState Key Lab of Superhard Materials, College of Physics, Jilin University, Changchun, 130012, People's Republic of China. jsliu@jlu.edu.cn.
Lesheng TengSchool of Life Sciences, Jilin University, Changchun, 130012, People's Republic of China. tenglesheng@jlu.edu.cn.
Hongdong LiState Key Lab of Superhard Materials, College of Physics, Jilin University, Changchun, 130012, People's Republic of China. hdli@jlu.edu.cn.ORCID http://orcid.org/0000-0002-5555-935X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blue light (BL) irradiation has been a potentially efficient treatment for many kinds of tumors. In this study, a BL irradiation (centered at 453 nm in wavelength) was proposed to treat the common human liver cancer cell lines of SMMC-7721 and HepG2, examined by means of flow cytometry, western blot, fluorescence microscope assay. In comparison to control groups, the apoptosis and proliferation inhibition of both BL-treated cells are expressively enhanced by mitochondrial apoptosis. The mechanism of apoptosis is related to the more production of reactive oxygen species (ROS) induced by BL and the corresponding changes in the expression of apoptosis-related Bcl-2, Bax and Bad proteins. In addition, the migration rate of the cancer cells could be reduced after BL irradiation. These results demonstrate that introducing BL irradiation is helpful to establish an effective and low toxicity strategy for the clinical treatment of liver tumors.

Indexed as

ApoptosisLiver NeoplasmsCell Line, TumorCell ProliferationHumansLightReactive Oxygen SpeciesReactive Oxygen SpeciesApoptosisBlue light irradiationLiver cancerProliferation inhibitionROSSMMC-7721 and HepG2 cell lines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.